Market Newsdesk

FARNBOROUGH, England, July 19, 2026 (GLOBE NEWSWIRE) — The GE Aerospace (NYSE: GE) GEnx-1B engine has surpassed the 50 million flight hour mark in just over 14 years, the fastest rate ever for GE Aerospace commercial widebody engine model.

The GEnx-1B, which powers the Boeing 787 Dreamliner family, is currently in service with more than 50 operators around the world and is averaging a total of over 600,000 flight hours monthly. The engine boasts a 99.98% dispatch reliability rate and stays on-wing at a rate three times higher than competing engines.

Mohamed Ali, President & CEO, GE Aerospace Commercial Engines & Services, said: “Airlines need engines that deliver reliability, durability, predictability, and efficiency across some of the world’s most demanding routes, and the GEnx-1B continues to do exactly that. Reaching 50 million flight hours for the GEnx-1B in less than 15 years is a remarkable milestone, and it reflects the trust our customers place in GE Aerospace every day.”

The GEnx engine family has more than 2,700 engines in service, including spares. The GEnx-2B has accumulated 24 million hours since entering service in 2011 on the Boeing 747-8. In total, the GEnx engine family has nearly 75 million flight hours and nearly 12 million cycles.

The long-haul flights the GEnx engine powers traverse some of Earth’s harshest environments. Over the last decade, GE Aerospace has upgraded the GEnx engine’s high-pressure turbine blades and combustor coating technology, more than doubling time on wing in harsh environments.

GE Aerospace is also investing $1 billion this year across our U.S. manufacturing sites and supply chain, with over $100 million dedicated to enhancing supplier capabilities for programs like the GEnx engine. These investments focus on increasing engine production capacity, modernizing facilities, and strengthening the supply chain to meet high demand.

Continued support through service innovation
GE Aerospace has implemented a number of on-wing technologies available for the GEnx, including:

360 Foam Wash: designed to break down and remove dust and dirt particles. GE Aerospace’s 360 Foam Wash can help improve engine compressor efficiency, reduce fuel consumption, lower CO2 emissions, and extend time between shop visits.

Blade Inspection Tool (BIT): This technology gives GEnx-1B and -2B customers clear and consistent insight during HPT Stage 1 & Stage 2 blade inspections. Blade inspectors with integral cameras capture images with cutting edge AI technology, extracting and presenting them for review. BIT enables the user to measure both lines and areas on blade surfaces, to make an accurate assessment of the condition of hardware.

FlightPulse: A GE Aerospace application developed for pilots to measure their fuel use and other statistics against those of their peers or against their own previous flights so they can self-discover areas to optimize operations and efficiency.

GEnx’s revenue-sharing participants are IHI Corporation of Japan, GKN Aerospace Engine Systems of the UK, MTU of Germany, TechSpace Aero (Safran) of Belgium, Safran Aircraft Engines of France and Samsung Techwin of Korea.

About GE Aerospace

GE Aerospace is a global aerospace propulsion, services, and systems leader with an installed base of approximately 50,000 commercial and 30,000 military aircraft engines. With a global team of approximately 57,000 employees building on more than a century of innovation and learning, GE Aerospace is committed to inventing the future of flight, lifting people up, and bringing them home safely. Learn more about how GE Aerospace and its partners are defining flight for today, tomorrow, and the future at www.geaerospace.com.

XFLT Hosts 

Webinar

on Benefits of the King Street Sub-Adviser

XFLT Asks Shareholders to Vote on the WHITE Proxy Card “FOR” the King Street Sub-Advisory Agreement at Special Meeting on July 30, 2026

CHICAGO, July 19, 2026 (GLOBE NEWSWIRE) — XA Investments LLC (“XAI”), manager of XAI Floating Rate & Alternative Income Trust (XFLT) (the “Fund”), shared an informational webinar featuring XAI President Kimberly Flynn, who spoke directly to XFLT shareholders on the benefits of the new investment sub-advisory agreement among the Fund, XA Investments LLC and Rockford Tower Asset Management, L.L.C. (the “King Street Sub-Adviser”), a wholly owned subsidiary of King Street Capital Management, L.P. (“King Street”) (the “King Street Sub-Advisory Agreement”) in the upcoming Special Meeting of Shareholders on July 30, 2026.

Flynn stated:

“There’s a number of different benefits, but I’ll focus on what the Board considered, and we’re really happy to talk about the potential positive benefits resulting from a change. Our XA Investments Management team and the Fund Board believe that King Street will benefit the fund in three main ways.

First, it’s a potential increase in distributions, and a potential for improved performance over time.

Second, King Street, their institutional quality investment management track record is significant, and, [third], King Street’s rigorous research and credit analysis, tactical trading capabilities and adaptive approach, so that they can tailor their management to meet each of the fund’s investment objectives is what we thought was important in terms of improving the outcomes for shareholders.”

How to Vote

The Board urges XFLT shareholders to vote “FOR” the King Street Sub-Adviser on the WHITE Card. Use one of the following options to vote:

• By Internet: Visit the website listed on your WHITE proxy card, enter your control number and follow the simple on-screen instructions.
• By Phone: Call the toll-free number listed on your WHITE proxy card.
• By Mail: Sign and return the enclosed WHITE proxy card in the enclosed postage-paid envelope.

If you have any questions or need assistance voting your shares please contact our proxy solicitation firm, Okapi Partners LLC, toll-free at (855) 305-0855 or by email at [email protected].

About XA Investments

XA Investments LLC is a Chicago-based firm founded by XMS Capital Partners in 2016. XAI serves as the investment adviser for two listed closed-end funds and an interval closed-end fund. In addition to investment advisory services, the firm also provides investment fund structuring and consulting services focused on registered closed-end funds to meet institutional client needs. XAI offers custom product build and consulting services, including product development and market research, marketing and fund management. XAI believes that the investing public can benefit from new vehicles to access a broad range of alternative investment strategies and managers. For more information, please visit www.xainvestments.com.

About King Street Capital Management

King Street is a global alternative investment firm founded in 1995 that manages $30 billion in assets across public and private markets. The firm marries rigorous fundamental research with tactical trading and differentiated sourcing capabilities to identify investment opportunities across asset classes, up and down the capital structure. For more information, please visit www.kingstreet.com. Follow King Street Capital Management on LinkedIn.

Forward-Looking Statements 

This press release contains certain statements that may include “forward-looking statements.” Forward-looking statements can be identified by the words “may,” “will,” “intend,” “expect,” “estimate,” “continue,” “plan,” “anticipate,” and similar terms and the negatives of such terms. By their nature, all forward-looking statements involve risks and uncertainties, and actual results could differ materially from those contemplated by the forward-looking statements. Many factors that could materially affect the Fund’s actual results are the performance of the portfolio of securities held by the Fund, the conditions in the U.S. and international financial and other markets, the price at which Fund shares trade in the public markets and other factors. Although the Fund believes that the expectations expressed in such forward-looking statements are reasonable, actual results could differ materially from those expressed or implied in such forward-looking statements. The Fund’s future financial condition and results of operations, as well as any forward-looking statements, are subject to change and are subject to inherent risks and uncertainties. You are cautioned not to place undue reliance on these forward-looking statements, which are made as of the date of this press release. Except for the Fund’s ongoing obligations under the federal securities laws, the Fund does not intend, and the Fund undertakes no obligation, to update any forward-looking statement.

This press release shall not constitute an offer to sell or a solicitation to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer or solicitation or sale would be unlawful prior to registration or qualification under the laws of such state or jurisdiction.

Past performance is no guarantee of future results. An investment in the Fund involves risk, including the possible loss of principal. Investors should consider the Fund’s investment objectives, risks, charges, and expenses carefully before investing. Please refer to the Fund’s filings with the Securities and Exchange Commission for additional information.

Media Contact: 

XA Investments LLC
Kim Shepherd
Senior Consultant
[email protected]
312-623-5123
www.xainvestments.com

Prosek Partners
[email protected]

• After a single intravitreal dose of 4D-150, visual acuity and anatomic control was maintained with consistent and durable treatment burden reduction through 2 years 
• 4D-150 continues to be well tolerated with no new safety or intraocular inflammation findings

EMERYVILLE, Calif., July 18, 2026 (GLOBE NEWSWIRE) — 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today announced positive 2-year data from the PRISM Phase 2b clinical trial evaluating 4D-150 in a broad wet age-related macular degeneration (wet AMD) population. The data were presented by Carl Awh, M.D., FASRS, Tennessee Retina, in an oral presentation titled “2-Year Follow Up: PRISM Phase 2b Clinical Trial Evaluating Investigational 4D-150, an Intravitreal Gene Therapy, in a Broad Neovascular AMD Population” at the 44^th Annual Scientific Meeting of the American Society of Retina Specialists (ASRS).

2-Year Data from PRISM Phase 2b Clinical Trial (Data Cutoff May 18, 2026):

Trial and Patient Cohort Overview

• The Phase 2b trial enrolled 45 patients at two dose levels of a single intravitreal dose of 4D-150 (3E10 and 1E10 vg/eye); 3E10 vg/eye was chosen as the dose for the 4FRONT Phase 3 clinical trials
• The Phase 2b overall cohort enrolled patients with broad disease activity (n=30 dosed with 3E10 vg/eye and n=15 dosed with 1E10 vg/eye)
• The Phase 2b cohort subgroup comprised recently diagnosed patients (diagnosed within 6 months, n=15 at 3E10 vg/eye), which is most comparable to the population enrolled in the 4FRONT Phase 3 clinical trials

Phase 2b Efficacy Results Through 2 Years:

• Consistent maintenance of best corrected visual acuity (BCVA)
• Consistent control of central subfield thickness (CST) as measured by optical coherence tomography
• Consistent, durable and clinically meaningful reduction in treatment burden:
  • Overall cohort:
    • 78% overall treatment burden reduction (2.7 mean supplemental injections per patient vs. 12.0 injections projected with on-label aflibercept 2 mg Q8W)
  • Recently diagnosed subgroup:
    • 87% overall treatment burden reduction (1.6 mean supplemental injections per patient vs. 12.0 injections projected with on-label aflibercept 2 mg Q8W)
• Dose response maintained throughout 2 years in favor of the Phase 3 dose

Safety Data for Phase 3 Dose in Overall PRISM Phase 1/2a & 2b Clinical Trial (n=71)

• 4D-150 continues to be well tolerated:
  • Intraocular inflammation:
    • As previously reported, within approximately the first 6 months (28 weeks) post-4D-150 dosing, 2.8% (2 of 71) of patients had 4D-150-related 1+ (mild) intraocular inflammation (IOI) (SUN/NEI scales), which were transient 1+ vitreous cells noted at a single timepoint
    • Following the first 28 weeks post-4D-150 dosing, no new cases of inflammation with 2 to more than 4 years of follow-up on all patients as of the data cutoff
  • No 4D-150-related hypotony, endophthalmitis, vasculitis, occlusive/non-occlusive retinal vasculitis or choroidal effusions observed to date

“Two-year PRISM data continue to strengthen our conviction in 4D-150’s potential to become a foundational backbone therapy for wet AMD,” said David Kirn, M.D., Co-founder, President, and Chief Executive Officer of 4DMT. “The continued consistency in visual acuity and anatomic control with meaningful reduction in treatment burden and long-term tolerability reinforces our confidence in delivering a transformative treatment option for retina specialists and their patients.”

“For retina specialists and our patients, maintaining the intensive injection schedule necessary to preserve vision is a tremendous challenge,” said Carl Awh, M.D., FASRS, Tennessee Retina. “The two-year PRISM results demonstrate the potential of a single intravitreal administration of 4D-150 to provide long-term anti-VEGF and sustained disease control. Reducing treatment burden will undoubtedly improve our ability to preserve vision over the long term for our patients.”

The presentation from ASRS is available on the 4DMT website under Scientific Presentations.

About 4D-150

4D-150 is a potential backbone therapy designed to provide multi-year, and potentially lifelong, sustained delivery of anti-VEGF biologics (aflibercept and anti-VEGF-C) within the retina following a single intravitreal injection. 4D-150 utilizes our customized and evolved intravitreal AAV vector, R100, which was invented at 4DMT through our proprietary Therapeutic Vector Evolution platform. 4D-150 is being developed for wet AMD and diabetic macular edema (DME), which both affect millions of patients globally, with the goal of freeing patients from burdensome injections while preserving vision.

About Wet AMD

Wet AMD, or wet age-related macular degeneration, is a highly prevalent disease, with more than 4 million individuals expected to be affected in the next five years in certain major markets, including the U.S., the EU and Japan. The disease also has a high incidence, with 200,000 individuals estimated to be newly diagnosed every year in the U.S. alone. Wet AMD is a type of macular degeneration in which abnormal blood vessels grow into the macula (macular neovascularization or MNV), the central area of the retina. MNV causes swelling and edema of the retina, bleeding and scarring, leading to visual distortion and reduced visual acuity. The proliferation and leakage of abnormal blood vessels is stimulated by VEGF. This process distorts and, without treatment, can potentially destroy central vision and may progress to blindness.

About 4DMT

4DMT is a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients. The Company’s lead product candidate 4D-150 is designed to be a backbone therapy forming the foundation of treatment of blinding retinal vascular diseases by providing multi-year sustained delivery of anti-VEGF biologics (aflibercept and anti-VEGF-C) with a single intravitreal injection, which substantially reduces the treatment burden associated with current bolus injections. The Company’s lead indication for 4D-150 is wet age-related macular degeneration, which is currently in Phase 3 development, and second indication is diabetic macular edema. The Company’s second product candidate is 4D-710, which is the first known genetic medicine to demonstrate successful delivery and expression of the CFTR transgene in the lungs of people with cystic fibrosis after aerosol delivery. 4D Molecular Therapeutics™, 4DMT™, Therapeutic Vector Evolution™, Backbone 4 Retina™ and the 4DMT logo are trademarks of 4DMT.  

All of the Company’s product candidates are in clinical or preclinical development and have not yet been approved for marketing by the U.S. Food and Drug Administration or any other regulatory authority. No representation is made as to the safety or effectiveness of the Company’s product candidates for the therapeutic uses for which they are being studied.

Learn more at www.4DMT.com and follow us on LinkedIn. 

Forward-Looking Statements:

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, implied and express statements regarding the therapeutic potential, treatment-burden reduction, durability, clinical development plans, regulatory timing, and success of clinical trials for 4D-150. The words “may,” “might,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “seek,” “predict,” “future,” “project,” “potential,” “continue,” “target” and similar words or expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based on management’s current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including risks and uncertainties that are described in greater detail in the section entitled “Risk Factors” in 4D Molecular Therapeutics’ most recent Quarterly Report on Form 10-Q filed on May 7, 2026, as well as any subsequent filings with the Securities and Exchange Commission. In addition, any forward-looking statements represent 4D Molecular Therapeutics’ current views and should not be relied upon as representing its views as of any subsequent time. 4D Molecular Therapeutics explicitly disclaims any obligation to update any forward-looking statements. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements.

Contacts:

Media:

Jenn Gordon
dna Communications
[email protected]

Investors:

Julian Pei
Head of Investor Relations and Strategic Finance
[email protected]

First UFC Event Ever to Be Held in Serbia, Scheduled for August 1, 2026 at Belgrade Arena

Meridianbet Leads the B2C Division of Meridian Holdings Inc. (NASDAQ: MRDN)

BELGRADE, Serbia, July 18, 2026 (GLOBE NEWSWIRE) — Meridian Holdings Inc. (NASDAQ: MRDN) (the “Company”) today announced that the Company’s subsidiary Meridianbet has been named Official Sponsor of UFC Fight Night Serbia, a mixed-martial-arts event produced by the Ultimate Fighting Championship (UFC), scheduled for August 1, 2026 at Belgrade Arena in Belgrade, Serbia.

The event will be the first UFC has ever held in Serbia, where Meridianbet will be its exclusive sponsor in the sports-betting category. The sponsorship will include branding inside the Octagon during the event, logo placement across official event marketing (including the fight poster and round cards), an in-venue commercial at Belgrade Arena and a digital and social media campaign across UFC’s web, video and social channels.

The event will air live in the United States on Paramount+ and will be distributed internationally through UFC’s broadcast partners, reaching a global audience.

“Serbia is where Meridianbet’s story began 25 years ago, and there is no bigger stage to mark that anniversary than UFC’s first-ever event in the country,” said William Scott, Chief Executive Officer of Meridian Holdings. “Combat sports sponsorship has long been part of our brand strategy, and partnering with one of the most-watched properties in global sports is a natural next step as we continue to build visibility for our firm across the region and the world.”

Meridianbet was founded in Serbia in 2001 and has since operated in the market continuously. The sponsorship deal with UFC marks the brand’s most visible association with a global sports property to date.

Meridianbet has sponsored combat sports for years, from elite professional cards to grassroots martial arts events, and the category remains one of the brand’s most visible. The partnership also reflects a long-running commitment to sport in the communities where the brand operates: across its markets, Meridianbet supports clubs, youth academies and local sports programs, from grassroots level to elite competition, alongside community initiatives in health and education.

About Meridian Holdings Inc.

Meridian Holdings Inc. (NASDAQ: MRDN), headquartered in Las Vegas, Nevada, is an established B2B and B2C gaming technology group operating across over 25 international regulated markets. The Company’s B2C division is led by Meridianbet Group, a leading online sports betting and gaming operator founded in 2001 and licensed across Europe, Africa, and South America. Meridian’s B2B division, comprising game developer Expanse Studios and iGaming platform GMAG, develops, licenses, and distributes proprietary gaming technology to a global client base. Additional subsidiaries include RKings Competitions (pay-to-enter prize competitions in the UK), MexPlay (regulated online casino in Mexico), and Classics for a Cause (Australia’s leading subscription-based digital memberships and trade-promotion lottery). The Company’s software automatically declines gaming or redemption requests originating in the United States, in strict compliance with U.S. law. For more information, visit www.meridian-holdings.com.

About UFC

UFC is the world’s premier mixed martial arts organization, producing more than 40 live events annually and distributing its programming to an estimated one billion broadcast and digital households across 210 countries and territories, with an athlete roster representing more than 75 countries. UFC is part of TKO Group Holdings, Inc. (NYSE: TKO) and is headquartered in Las Vegas, Nevada. For more information, visit UFC.com.

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that are subject to the safe harbor created by the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, statements regarding the anticipated staging of the UFC event in Belgrade, Serbia on August 1, 2026; the expected scope, benefits and duration of the sponsorship, including anticipated branding, marketing, advertising, digital and social media elements and the expected exclusivity in the sports-betting category in the Serbian market; the anticipated broadcast and distribution of the event in the United States and internationally; the anticipated visibility, brand, marketing or commercial benefits of the partnership to the Company; and statements regarding the Company’s strategy, growth plans and market position. Words such as “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “project,” “will,” “would,” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words.

Forward-looking statements are based on the Company’s current expectations and assumptions and involve known and unknown risks and uncertainties, many of which are beyond the Company’s control, that could cause actual results, events or outcomes to differ materially from those expressed or implied in such statements. Important factors that could cause actual results to differ materially include, without limitation: (a) the risk that the event is postponed, canceled, relocated, rescheduled or otherwise modified, including as a result of circumstances outside the control of the Company or the event organizer; (b) the right of either party to terminate or modify the sponsorship agreement in accordance with its terms, including in response to regulatory developments; (c) the risk that certain sponsorship benefits become unavailable and are substituted or otherwise modified; (d) the Company’s dependence on third parties, including the event organizer, the venue, broadcasters, distribution partners and other rights holders, whose decisions and performance are outside the Company’s control; (e) the need to obtain approvals for marketing and promotional materials and the risk that such approvals are delayed, conditioned or withheld; (f) the scope of, and contractual limitations on, the Company’s sponsorship and category exclusivity rights; (g) changes in laws, regulations or regulatory guidance applicable to gaming, sports wagering, advertising or sponsorship in Serbia or in other jurisdictions in which the Company operates, and the Company’s ability to obtain and maintain required licenses, permits and approvals; (h) the risk that the anticipated marketing, brand or commercial benefits of the sponsorship are not realized in whole or in part; and (i) the other risks and uncertainties described in the Company’s filings with the U.S. Securities and Exchange Commission, including its most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K, available at www.sec.gov.

The forward-looking statements included in this press release speak only as of the date hereof. The Company cannot guarantee future results, levels of activity, performance or achievements, and readers should not place undue reliance on these forward-looking statements. Except as required by law, the Company undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, and no inference should be drawn that the Company will make additional updates with respect to those or other forward-looking statements. The Company assumes no obligation to update or correct information prepared by third parties that is not paid for by the Company.

Investors & Press:

ICR

[email protected]

Meridian Holdings Inc.

[email protected]

Fees Will 


NOT


Increase If Proposal Is Approved

Terminated Sub-Adviser Octagon’s “Proven Investment Team” Responsible for -54% NAV Erosion at XFLT and Seven CLO Defaults Across Its Own Portfolio

XFLT Asks Shareholders to Vote on the WHITE Proxy Card “FOR” the King Street Sub-Advisory Agreement at Special Meeting on July 30, 2026

CHICAGO, July 18, 2026 (GLOBE NEWSWIRE) — XA Investments LLC (“XAI”), manager of XAI Floating Rate & Alternative Income Trust (XFLT) (the “Fund”), responded to misleading claims regarding the approval of a new investment sub-advisory agreement among the Fund, XAI and Rockford Tower Asset Management, L.L.C. (the “King Street Sub-Adviser”), a wholly owned subsidiary of King Street Capital Management, L.P. (“King Street”) at the upcoming Special Meeting of Shareholders on July 30, 2026.